encorafenib,Binimetinib,Cetuximab
pfizer,ono pharmacueticals,pierre fabre,eli lilly
[]
 ..or at least a synthetic control arm. i'm sensing a move away from the use of single arm trials, especially in untreated patients. if you need an answer to a question then do it properly, some may say....but i guess the other question here is sequencing of these therapies
Oncology drug development in biotech. Pro-EU. Francophile. Home is Castelsagrat, Tarn-et-Garonne. Views my own. 🌈🇬🇧🇨🇵